Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update
08.08.2022 - - Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) - Celldex ...
Garry Neil Sarah Cavanaugh Anthony Marucci Cheryll Cohen Shareholder Representative Services Agonist Program
Source: wallstreet-online.de